603 Page 1 05-Oct-2026To Company Name/SchemeACN/ARSN1. Details of substantial holder (1)NameACN/ARSN (if applicable)The holder became a substantial holder on01/10/20262. Details of voting powerThe total number of votes attached to all the voting shares in the company or voting interests in the...
Becoming a substantial holder
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Corporate governance statement
- Appendix 4G
- Annual Report to shareholders
- Ceasing to be a substantial holder
- Date of Annual General Meeting 25 November 2026
Later from Clarity Pharmaceuticals
- SECuRE update
- SAR-bisPSMA Presentation - Drug & Device Conference
- Notice of Annual General Meeting/Proxy Form
- Ph III CLARIFY trial target number of participants achieved
- Quarterly Activities/Appendix 4C Cash Flow Report
